Contact Information: Contacts: Investor Relations Andrew Barwicki 516.662.9461 Website: www.nanologix.net
NanoLogix Exhibiting at National Hydrogen Association Conference
| Source: NanoLogix, Inc.
SHARON, PA -- (MARKET WIRE) -- March 20, 2007 -- NanoLogix, Inc. (PINKSHEETS : NNLX ) announced
today that the company is exhibiting both their Hydrogen Bioreactor
Technology and Hydrogen Engine Conversions at the 2007 National Hydrogen
Association Annual Conference in San Antonio
http://www.hydrogenexpo.com/.
Senior Vice President William Hartman of NanoLogix and David Hartman, the
Chief Engineer and President of NanoLogix's hydrogen engine conversion
partner, Precision Performance Company, will be in Booth #146 March 20th
and 21st. In addition, Research Paper #3306 "Microbial Production of
Hydrogen from Sugar-rich Wastewater" by Gannon University Associate
Professor Dr. Harry Diz will be presented. Dr. Diz has managed research
at NanoLogix pilot hydrogen bioreactor at Welch's Grape Juice Factory. The
research paper documents the results achieved. Dr. Diz concludes in the
paper "Hydrogen production was sustained over more than six months of
operation while methane production was controlled and limited. This
experience confirmed the ability to maintain a hydrogen-generating culture
in an industrial setting over an extended period of time."
Dana Allen, Vice President of Strategic Partnering for NanoLogix, stated,
"The advantage NanoLogix has in hydrogen production is that unlike
conventional hydrogen production that requires the wasteful use of natural
gas or electricity, our bioreactor actually creates energy (hydrogen) out
of wastewater. It not only produces hydrogen as a renewable source of
energy, it also cleans the water. Hydrogen is known as a wonderful and
environmentally friendly fuel to use, which it is, the problem is how to
create it, energy density, storage and transportation. The patented
NanoLogix bioreactor shows great promise to solve the remaining problems.
By producing from wastewater (generally a free feedstock) and immediately
converting it to electrical, mechanical or heat power on site, all these
issues are covered. The existing highly efficient electrical grid becomes
the method of transportation when the power generated exceeds local
demand. We look forward to large scale implementation of this technology."
This year, for the first time Hydrogen Expo US features a
Hydrogen-from-Renewables Pavilion with four exhibitors: NanoLogix,
Powertech Labs, Ecotality and Sandia National Laboratories. "We expect
this pavilion to grow in future years," commented an Expo
official. "Additionally, exhibitors such as Ballard or Proton Power
Systems, whose products integrate easily with renewable energy
technologies, will have individual displays," as noted in an EarthToys.com
article (link: http://www.earthtoys.com/news.php?section=view&id=2225).
NanoLogix hydrogen engine conversions have been well received in the market
with sales in the first month of availability. Current prices range from
$1,100 for a Briggs&Stratton 7.5 HP engine to $2,200 for 5.5 KW generator
with a Briggs&Stratton 10 HP engine. These prices include hydrogen
regulators and hose. A video of a Hydrogen engine conversion running and a
WICU-TV news program on NanoLogix Bioreactor pilot plant are available for
viewing on Nanologix website at http://www.nanologix.net/in_action.php.
The engine conversion video will be updated later with a professional
video.
About NanoLogix, Inc.
NanoLogix is an industry innovator in the research, development, and
commercialization of nano-biotechnologies, applications and processes. The
Company has developed and owns or has rights to 32 patents related to
various medical technologies, 5 of which also have hydrogen-generation
aspects. In the past year the Company has filed an additional 28 patent
applications for discoveries related to hydrogen bioreactors, medical
testing, and innovative medical treatments potentially related to leukemia
and sepsis. NanoLogix is presently operating a hydrogen bioreactor at
Welch's Food and has recently signed an agreement with the City of Erie
Wastewater Treatment Plant for a prototype bioreactor installation. While
much of the Company's current focus is on the production of hydrogen from
agricultural feedstock, industrial wastewater and municipal waste streams
in an effort to meet the need for economic sources of clean fuel, the
medical heritage of the Company has not been neglected. NanoLogix-developed
patents are used to design and market diagnostic test kits for use in early
detection of the bacteria present in infectious and noninfectious human
diseases such as tuberculosis, pneumonia, HIV/AIDS, cancer, and cystic
fibrosis. The company also owns a patent for the non-toxic induction of
apoptosis ('cell suicide') for the treatment of cancer. For more
information on the Company, visit http://www.nanologix.net.
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of
NanoLogix, Inc., and members of its management as well as the assumptions
on which such statements are based. Prospective investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results
may differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or revise
forward-looking statements to reflect changed assumptions, the occurrence
of unanticipated events or changes to future operating results.